RCEL · Avita Medical, Inc.

The thesis

AVITA Medical's shares set a new 52-week high on guidance that no new quarter has yet tested: $86–89 million of 2026 revenue and cash-flow breakeven in the fourth quarter. The third-quarter report settles it. StockAnalysis lists that report for around 4 November 2026, and the company had not announced a date as of 16 October 2026. The report will show whether net cash use kept falling from the $3.2 million reported for the second quarter.

The shares closed at $13.41 on 15 October 2026, a new 52-week high in adjusted daily closes, above the prior high of $13.37 set on 12 October 2026. They are up 160.9% over three months. The 14-day relative strength index (RSI), a 0–100 momentum gauge, stood at 71.4, just above the 70 level usually read as overbought.

The business facts have not changed since the 15 October 2026 note. Searches of company releases on 16 October 2026 found no results date, guidance change or financing. The latest new fact is still BTIG's target raise to $15 from $11 on 12 October 2026.

The narrative is maturing: the guidance and the breakeven goal have been public since 6 August 2026, and the climb to the 15 October 2026 high came on analyst target changes and conference restatements, with no new numbers reported. The case stays modestly positive because cash use had already fallen sharply by June. Third-quarter net cash use at or above $3.2 million would break it.

Bullish and bearish views on Avita Medical, Inc.

The bull case on Avita Medical, Inc. (RCEL), in brief: Cash use is falling fast. The bear case: Liquidity is thin against debt.

Bull case

• Cash use is falling fast. Net cash use was $3.2 million in the second quarter of 2026, down from $9.9 million in the first quarter, per the company's 6 August 2026 release. The same release forecast cash-flow breakeven in the fourth quarter of 2026.
• Revenue growth picked up. Second-quarter revenue rose 18% year over year and 13% from the first quarter, to $21.7 million, per the 6 August 2026 release. Gross margin was 81.9%, and operating expenses fell 6% to $24.6 million.
• Guidance raised, then restated. On 6 August 2026 the company lifted its 2026 revenue guide to $86–89 million from $80–85 million, which it said means 20–24% growth over 2025's $71.6 million. Management restated the range and the breakeven target at the Morgan Stanley Global Healthcare Conference on 16 September 2026, according to Investing.com's summary, and put quarterly operating expense at about $24 million.
• Reimbursement holds for 2027. On 16 September 2026 management said the 2027 national physician payment rules keep Category I procedure coding for RECELL, the company's spray-on skin-cell device for burns and wounds.
• Analyst targets moved up. BTIG raised its target to $15 from $11 on 12 October 2026, the top of a $10–15 range across seven analysts, per MarketBeat. Five of those seven rate the shares Buy.

Bear case

• Liquidity is thin against debt. At 30 June 2026, AVITA held $11.1 million of cash and marketable securities against $46.7 million owed under its Perceptive credit facility, up from $42.9 million at the end of 2025, per the second-quarter release. A further $10 million tranche requires $85 million of trailing-twelve-month revenue before 31 March 2027.
• Strength invites share issuance. The weighted-average share count was 30.7 million in the second quarter. With the shares at a 52-week high on 15 October 2026 and liquidity at $11.1 million in June, a registered share sale would dilute holders and could cap the price.
• Price is ahead of most targets. The $13.41 close on 15 October 2026 sits above the $12.20 consensus target, per MarketBeat, and within 11% of BTIG's $15, the highest on the Street.
• Crowding is visible. The 160.9% three-month gain and a 14-day RSI of 71.4 on 15 October 2026 came before any new quarter was reported, and the next report is roughly three weeks out. A small share count has already produced a single-session move above 50%, on 7 August 2026.

Price setup

The 7 August 2026 session, after the second-quarter report, moved the shares into a higher range. They have trended up since mid-September and closed at a 52-week high of $13.41 on 15 October 2026.

The $9.00 level marks the lower part of the range traded after the August jump. A weekly close below $9.00 would hand back most of the advance since mid-September and mark the rally as one that ran ahead of the business. Above, the consensus target of $12.20 has already been passed, and BTIG's $15 is the only published target higher than the 15 October 2026 close.

Catalysts, next 30 days

• ~28 October 2026 (est.): results-date announcement. AVITA announced its Q3 2025 date on 29 October 2025 for a 6 November 2025 report, and its Q2 2026 date on 14 July 2026 for a 6 August 2026 report, per company releases. The notice fixes the date of the first reported test of the raised guide.
• ~4 November 2026 (est.): third-quarter 2026 results. StockAnalysis lists this date. The company has reported recent quarters on Thursdays after the US close, so 5 November 2026 is also possible. The report shows whether net cash use fell below $3.2 million and whether revenue tracks the $86–89 million full-year guide.
• 31 March 2027: Perceptive tranche deadline. Reaching $85 million of trailing-twelve-month revenue unlocks $10 million of further debt. Missing it raises the odds that new funding comes from selling shares.

What would change the view

The case breaks if third-quarter net cash use comes in at or above the second quarter's $3.2 million, or if management moves cash-flow breakeven out of the fourth quarter of 2026. A cut to the $86–89 million revenue guide would break it too, and would also threaten the $85 million revenue condition on the Perceptive tranche.

A registered share offering or at-the-market program announced before breakeven would weaken the case through dilution, even with guidance intact. On price, a weekly close below $9.00 would end the thesis on its own.

A third-quarter report with cash use well below $3.2 million, revenue consistent with the top of the guide, and no new equity would strengthen it.

What it trades with

AVITA sits in the medtech and diagnostics group, which has heated up in each weekly reading since 27 September 2026. Its business overlaps little with the group's diagnostics and sequencing peers, such as Illumina, GRAIL and Quanterix. Its biggest moves, such as the 7 August 2026 jump, have followed its own reports more than the group's.

As a small company with a short cash runway, the shares are exposed to swings in appetite for small-cap and funding-dependent medtech. A cooling of the group would raise the bar for the third-quarter report without changing the cash-use test that decides the case.